Skip to content
Breast imaging clinician marking a follow-up appointment on a calendar for a BI-RADS 3 result.

HER2 IHC 2+ in Breast Cancer: Why Another Test Is Needed

CancerSnoop Test Guide
HER2 IHC 2+ in Breast Cancer: Why Another Test Is Needed

A pathology report may list an initial HER2 stain before the lab issues the final interpretation.

At a glance
Test Name HER2 immunohistochemistry and reflex in situ hybridization
Test Type Biomarker test
What It Measures IHC examines HER2 protein staining. ISH assesses copies of the HER2 gene in tumor cells.
Used For Clarify HER2 status to inform treatment selection.
Typical / Reference Range IHC is scored 0, 1+, 2+ or 3+ under defined criteria.

What HER2 IHC 2+ means in the first report

HER2 is a protein that can be present on breast cancer cells. Immunohistochemistry, abbreviated IHC, uses staining to assess the protein. A score of 2+ means the pattern requires further testing or review under the laboratory criteria. The IHC score is one part of the report. A pending notation can mean that the laboratory has started the additional test and will issue an addendum. [1] [2]

What the ISH test adds

ISH is short for in situ hybridization. The laboratory uses it to evaluate HER2 gene copies in the tumor cells. Some reports call the method FISH, a type of ISH that uses fluorescent signals. The pathologist applies the testing criteria to the pattern of gene signals and, when required, reviews the IHC and ISH findings together. The final interpretation is more useful to the reader than trying to interpret a single gene ratio without the rest of the report. [2]

How to read the words “HER2-low”

Clinical trials and certain drug eligibility criteria use the term HER2-low for specific IHC findings, including IHC 2+ with a negative ISH result. That language is used for a treatment question in defined settings. The CAP and ASCO testing guideline does not create a separate HER2-low interpretive category. Eligibility for a specific treatment still depends on the indication, the clinical situation and current guidance. A report can therefore document both an IHC score and a separate final HER2 interpretation. [1] [2] [3]

When the result belongs to a different specimen

A core biopsy, surgical specimen or biopsy from another site can each have a separate result. Match the test and interpretation to the specimen listed at the top of the page. If one report includes a result from an outside lab, ask whether the treatment team considers that result sufficient or wants to review tissue locally. It can be especially useful to hold onto the full report if treatment options are being considered at a later point.

What to ask if you are waiting for the final result

Ask whether ISH was ordered, whether it was sent to another lab and when the integrated interpretation is expected. If an appointment is already booked, ask whether the result should be available in time for the treatment discussion. Once the result is back, ask how it affects the options alongside ER, PR and the cancer stage. These questions clarify which information is missing and which decision it will inform.

How to avoid mixing up numbers

Write down the full name of each test next to its result. An IHC score describes a staining pattern. An ISH ratio or gene copy number describes a different measurement. A clinician reading the whole report can show which fields establish the final interpretation and which are supporting details.

Sources and References

  1. Breast Cancer Biomarkers
  2. HER2 Testing in Breast Cancer – 2023 Guideline Update
  3. Breast Cancer Treatment (PDQ®)
SHARE THIS EVIDENCE
WhatsApp ↗
Back To Top